AI Article Synopsis
- The study aims to assess the effectiveness of mycophenolate mofetil (MMF) in treating chronic inflammatory demyelinating polyneuropathy (CIDP).
- Researchers analyzed data from 184 CIDP patients, focusing on eight who were treated with MMF, noting significant improvements in their Neuropathy Impairment Scores.
- Findings indicate that MMF may be a promising therapy for CIDP patients, suggesting the need for further controlled studies to confirm these results.
Article Abstract
Objective: To evaluate the efficacy of mycophenolate mofetil (MMF) in chronic inflammatory demyelinating polyneuropathy (CIDP).
Background: Evidence is growing that MMF is effective as an immunomodulatory drug in neuromuscular diseases.
Methods: A database of 184 patients with CIDP was analysed to obtain clinical, laboratory and electrophysiological information for patients with CIDP treated with MMF.
Results: Eight patients, who met the inclusion criteria, received MMF (mean dose 2 g/day; median duration 15.2 months). The average Neuropathy Impairment Score of the eight patients improved from baseline (72.3+/-35) after initiation of MMF therapy (37.8+/-37; p<0.001). Six of these eight patients were either able to stop concomitant medications (corticosteroid, intravenous immunoglobulin) or reduce their doses and frequency by > or = 50%.
Conclusions: Our pilot data suggest that MMF appears to be an effective therapy for patients with naive or refractory CIDP, and further controlled studies are warranted for their confirmation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/jnnp.2009.177576 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!